Advanced Inhalation Therapies (AIT), which is developing inhaled nitric oxide therapies for cystic fibrosis and other indications, has filed a request to withdraw its registration statement for an initial public offering. The company announced its initial filing for the IPO in August 2015, saying that it planned to raise up to $36 million to support Phase 2 … [Read more...] about Advanced Inhalation Therapies files to withdraw IPO
Business
Fidelity increases its holding in Adherium to 10%
Smartinhaler maker Adherium has announced an upcoming $8 million AUD ($6 million USD) share placement to Fidelity International, increasing Fidelity's holdings in the company to 10%. The shares will be issued on July 26, 2016. According to Adherium, the purpose of the placement was to raise funds for working capital. Adherium CEO Garth Sutherland commented, … [Read more...] about Fidelity increases its holding in Adherium to 10%
Windtree Therapeutics gets $1 million for aerosolized KL4 surfactant development
Windtree Therapeutics (formerly Discovery Laboratories) said that it has received an additional $1 million from a Phase 2 Small Business Innovation Research (SBIR) grant initially announced in October 2014. The grant, with a total potential value of $3 million, supports development of the company's aerosolized KL4 surfactant as a treatment for radiation-induced lung … [Read more...] about Windtree Therapeutics gets $1 million for aerosolized KL4 surfactant development
Therapix Biosciences licenses intranasal cannabinoid formulation from Hebrew University
Therapix Biosciences has entered into an agreement with the Hebrew University's technology transfer company Yissum to obtain an exclusive worldwide license for an intranasal formulation of cannabinoids developed by Elka Touitou of the university's Institute of Drug Research, the company said. The news comes one week after the company, which is developing cannabinoids … [Read more...] about Therapix Biosciences licenses intranasal cannabinoid formulation from Hebrew University
Savara Pharmaceuticals acquires Serendex, inhaled molgramostim
AeroVanc developer Savara Pharmaceuticals has acquired Serendex Pharmaceuticals, which is developing Molgradex inhaled granulocyte-macrophage colony-stimulating factor (molgramostim) for the treatment of autoimmune pulmonary alveolar proteinosis (PAP). Serendex announced in September 2015 that it was initiating a Phase 2 clinical trial of Molgradex, which is delivered … [Read more...] about Savara Pharmaceuticals acquires Serendex, inhaled molgramostim
Ferrer completes merger with Alexza
In May 2016, Grupo Ferrer announced that it would acquire inhaled drug company Alexza Pharmaceuticals; as of June 21, 2016, the company says, Ferrer Pharma has merged into Alexza Pharmaceuticals, with Alexza now a wholly owned subsidiary of Ferrer. Ferrer already marketed Alexza's Staccato inhaled loxapine in much of the world and had become Alexza's largest … [Read more...] about Ferrer completes merger with Alexza
Nephron Pharmaceuticals launches generic budesonide inhalation suspension
US generic inhalation solutions manufacturer Nephron Pharmaceuticals has licensed Apotex's generic budesonide inhalation suspension, a generic version of AstraZeneca's Pulmicort Respules, and subsequently launched the product in the US, the company said. Nephron will manufacture, market, and distribute 0.5mg/2mL and 0.25mg/2mL dosage forms. The company's other … [Read more...] about Nephron Pharmaceuticals launches generic budesonide inhalation suspension
MannKind partners with JDRF on pediatric use of Afrezza
MannKind Corporation has announced that it signed an agreement with JDRF (formerly the Juvenile Diabetes Research Foundation) to collaborate on research focused on the use of Afrezza inhaled insulin in pediatric diabetes patients. JDRF is the largest non-profit funder of type 1 diabetes research in the world, according to the organization. The FDA approved … [Read more...] about MannKind partners with JDRF on pediatric use of Afrezza
Innovus Pharmaceuticals updates on plans for OTC FlutiCare nasal spray
California-based Innovus Pharmaceuticals announced that it has signed a manufacturing agreement for its FlutiCare fluticasone propionate nasal spray in anticipation of FDA approval, which it expects in the 3rd quarter of 2016. No details were revealed. The company acquired rights to the nasal spray in February 2015; an ANDA for the OTC version had been filed by … [Read more...] about Innovus Pharmaceuticals updates on plans for OTC FlutiCare nasal spray
Perrigo and Hikma get FDA approval for and launch generic fluticasone propionate nasal spray
Perrigo and Hikma subsidiary West-Ward Pharmaceuticals have launched an OTC fluticasone propionate nasal spray, a generic version of Flonase, in the US after receiving approval for the product from the FDA, the companies said. The nasal spray will be marketed under store brand names. Flonase was approved for over-the-counter sales in the US in 2014. Hikma … [Read more...] about Perrigo and Hikma get FDA approval for and launch generic fluticasone propionate nasal spray